Skip to main content
. 2019 Aug 17;105(24):1868–1875. doi: 10.1136/heartjnl-2019-315103

Table 1.

Patient characteristics

All
(n=46)
Stable atherosclerosis
(n=27)
Unstable atherosclerosis
(n=19)
P value*
Age (years) 67 (60–74) 69 (66–74) 60 (51–70) 0.01
Male sex 34 (74) 20 (74) 14 (74) 0.97
BMI (kg/m2) 28 (25–31) 28 (24–30) 27 (25–32) 0.39
Systolic BP (mm Hg) 140 (124–160) 149 (134–167) 125 (114–139) <0.001
18F-Fluciclatide dose (MBq) 229 (217–237) 228 (217–236) 229 (215–240) 0.69
Cardiovascular history
 Angiographically documented CAD 26 (57) 7 (26) 19 (100) <0.001
 Prev MI 24 (52) 5 (19) 19 (100) <0.001
 Prev PCI 20 (43) 2 (7) 18 (95) <0.001
 Prev CVD 4 (11) 4 (14) 0 (0) 0.08
Risk factors
 Current smoker 9 (20) 1 (4) 8 (42) 0.001
 Diabetes mellitus 6 (13) 4 (14) 2 (10) 0.58
 Prior hypertension 23 (50) 18 (67) 6 (32) 0.02
 Prior hypercholesterolaemia 25 (54) 12 (44) 12 (63) 0.21
 hs-CRP (mg/L) 3.5 (1.4–7.8) 2.7 (1.4–5.8) 5.6 (2.0–11.7) 0.08
Medications
 Aspirin 28 (61) 10 (37) 19 (100) <0.001
 Clopidogrel 19 (41) 4 (14) 19 (100) <0.001
 Statin 31 (67) 13 (48) 19 (100) <0.001
 β-Blocker 27 (59) 8 (30) 19 (100) <0.001
 ACEi/ARB 31 (67) 10 (37) 18 (95) <0.001
 Calcium channel blocker 7 (15) 6 (22) 1 (5) 0.11

Categorical data are displayed as n (%).

Continuous data are displayed as median (IQR).

*P values are quoted for comparisons between matched stable and unstable groups.

ACEi, ACE-inhibitor; ARB, angiotensin receptor blocker; AS, aortic stenosis; BMI, body mass index; BP, blood pressure; CAD, coronary artery disease; CVD, cerebrovascular disease; IHD, ischaemic heart disease; MI, myocardial infarction; PCI, percutaneous coronary intervention; hs-CRP, high-sensitivity C reactive protein.